Overview

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Status:
Terminated

Trial end date:
2020-11-17

Target enrollment:

Participant gender:

Summary

Primary Objective: To demonstrate the non-inferiority of once weekly injection of efpeglenatide in comparison to once weekly injection of dulaglutide on glycated hemoglobin (HbA1c) change in participants with Type 2 diabetes mellitus (T2DM) inadequately controlled with metformin. Secondary Objectives: - To demonstrate the superiority of once weekly injection of efpeglenatide with once weekly injection of dulaglutide on glycemic control. - To demonstrate the superiority of once weekly injection of efpeglenatide with once weekly injection of dulaglutide on body weight. - To evaluate the safety of once weekly injection of efpeglenatide and once weekly injection of dulaglutide.

Phase:

Phase 3

Details

Lead Sponsor:

Sanofi

Collaborator:

Hanmi Pharmaceutical Company Limited

Treatments:

Dulaglutide
Efpeglenatide
Immunoglobulin Fc Fragments
Metformin